Source: Medical Device Network

CSI: CSI begins subject enrolment in Diamondback 360 Peripheral OAS trial

The trial will support the regulatory approval of Diamondback 360 Peripheral OAS in Japan. The post CSI begins subject enrolment in Diamondback 360 Peripheral OAS trial appeared first on Medical Device Network.

Read full article »

CSI's Competitors | CSI's News | CSI's Financials

Followers on Owler

206

Est. Annual Revenue

$100-500M

Est. Employees

250-500

Chairman & CEO

Scott R. Ward

CEO Approval Rating

63/100

CSI is a Minnesota-based medical device company that develops and commercializes interventional products for the treatment of peripheral and coronary vascular diseases.